MINERALYS THERAPEUTICS, INC.
MLYSLoading price...
Overview
Previous Close28.85
Open26.48
Ask30.57
Bid18.94
Day's Range23.65 - 26.78
52 Week Range12.59 - 47.65
PE Ratio(TTM)--
Market Cap2.07B
Volume4.95M
Avg. Volume1.27M
12 Months Earnings-151.78M
12 Months Revenue0.00
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 171.50M | 170.60M | 192.40M | 84.66M | 31.48M |
| Profit after Tax (Net Income) | -151.78M | -154.65M | -177.81M | -71.90M | -29.80M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Radnor, United States
Website: https://mineralystx.com
President, CEO & Director: Mr. Jon Congleton
Employees: 76
About Company:
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.